Warning! GuruFocus detected
2 Severe warning signs
with 0RA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
RAPT Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75382E1091
Share Class Description:
FRA:0RA: Ordinary SharesDescription
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.44 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -9.9 | |||||
| 3-Year EPS without NRI Growth Rate | -8 | |||||
| 3-Year FCF Growth Rate | 3.2 | |||||
| 3-Year Book Growth Rate | -38.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 48.23 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.57 | |||||
| 9-Day RSI | 40.25 | |||||
| 14-Day RSI | 42.8 | |||||
| 3-1 Month Momentum % | -37.66 | |||||
| 6-1 Month Momentum % | -44.97 | |||||
| 12-1 Month Momentum % | -87.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | |||||
| Quick Ratio | 4.87 | |||||
| Cash Ratio | 4.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -64.7 | |||||
| Shareholder Yield % | -106.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -96.55 | |||||
| ROA % | -80.65 | |||||
| ROIC % | -896.63 | |||||
| 3-Year ROIIC % | -1804.96 | |||||
| ROC (Joel Greenblatt) % | -2188.12 | |||||
| ROCE % | -98.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.64 | |||||
| EV-to-Forward-EBIT | -0.63 | |||||
| EV-to-EBITDA | 0.64 | |||||
| EV-to-Forward-EBITDA | -0.64 | |||||
| EV-to-Forward-Revenue | 242.61 | |||||
| EV-to-FCF | 1.04 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Price-to-Net-Current-Asset-Value | 0.76 | |||||
| Price-to-Net-Cash | 0.78 | |||||
| Earnings Yield (Greenblatt) % | 156.25 | |||||
| FCF Yield % | -59.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RAPT Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.899 | ||
| Beta | 0.45 | ||
| 3-Year Sharpe Ratio | -0.51 | ||
| 3-Year Sortino Ratio | -0.74 | ||
| Volatility % | 84.71 | ||
| 14-Day RSI | 42.8 | ||
| 14-Day ATR (€) | 0.069337 | ||
| 20-Day SMA (€) | 1.093 | ||
| 12-1 Month Momentum % | -87.12 | ||
| 52-Week Range (€) | 0.945 - 8.65 | ||
| Shares Outstanding (Mil) | 132.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RAPT Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RAPT Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
RAPT Therapeutics Inc Frequently Asked Questions
What is RAPT Therapeutics Inc(FRA:0RA)'s stock price today?
The current price of FRA:0RA is €1.00. The 52 week high of FRA:0RA is €8.65 and 52 week low is €0.95.
When is next earnings date of RAPT Therapeutics Inc(FRA:0RA)?
The next earnings date of RAPT Therapeutics Inc(FRA:0RA) is 2025-05-09 Est..
Does RAPT Therapeutics Inc(FRA:0RA) pay dividends? If so, how much?
RAPT Therapeutics Inc(FRA:0RA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers